Please Wait.....
Report
Japan Breast Cancer Treatment Market Assessment, By Type [Ductal Carcinoma In Situ, Invasive Ductal Carcinoma, Lobular Carcinoma In Situ, Invasive Lobular Cancer, Triple Negative Breast Cancer, Inflammatory Breast Cancer, Metastatic Breast Cancer, Breast Cancer During Pregnancy, Other Types], By Treatment Type [Surgery, Radiation Therapy, Chemotherapy, Hormonal Therapy, Targeted Therapy, Immunotherapy, Others], By End-user [Cancer Research Institutes, Hospitals, Ambulatory Surgical Centers, Others], By Region, Opportunities and Forecast, FY2019-FY2033F
Market Report I 2025-06-16 I 128 Pages I Market Xcel - Markets and Data
Japan breast cancer treatment market is projected to witness a CAGR of 8.80% during the forecast period FY2026-FY2033, growing from USD 1.38 billion in FY2025 to USD 2.71 billion in FY2033. The market's growth can be attributed to the increasing cases of breast cancer in the country, rising investments by the key players of the market towards the launch of new therapies, and growing emphasis on research activities to combat the rising threat of the condition. As per the estimates of the Global Cancer Observatory, breast cancer was the leading type of cancer in women in Japan in 2022, accounting for 21.6% of all cancer cases.
The growth of the country's geriatric population, rising requirement for effective therapies, increasing government approvals, and rising research efforts are some of the major factors influencing the growth and expansion of the breast cancer treatment market in Japan. Meanwhile, the rising efforts of both public and private organizations to promote awareness about breast cancer and support early screening are also bolstering the market demand. The country's healthcare system is further supporting market growth by ensuring the affordability and accessibility of cancer therapies through public insurance coverage.
Increasing Research Activities Support Market Expansion
Rising research activities by leading research centers and educational institutions across the country are positively influencing the market's expansion by bolstering the availability of novel therapeutic solutions. The research ecosystem is also accelerating the introduction of advanced surgical techniques and drugs that allow oncologists to improve treatment outcomes and enhance patient experience. For instance, in February 2024, researchers at Tohoku University announced that they had developed a novel monoclonal antibody that targets HER2-positive breast cancer cells. The antibody represents a significant advancement in breast cancer treatment as well as a promise for the availability of less toxic and more effective treatment options, as the antibody offers a more selective and targeted approach as compared to conventional treatment options, including chemotherapy.
Technological Advancements Boost Market Growth
Increasing emphasis on technological advancements are significantly driving the growth of the market by improving diagnosis, expanding the availability of therapeutic solutions, and enabling precision medicine. Artificial intelligence and machine learning are enhancing the accuracy and speed of breast cancer detection through advanced imaging and mammography, resulting in the diagnosis of the condition in a time efficient manner. Additionally, the integration of multi-gene panel tests and genomic medicine has facilitated the development and adoption of targeted therapies, allowing clinicians to tailor the treatments according to the genetic profile of the patient.
Meanwhile, innovative treatment solutions launched by leading research organizations in the country are revolutionizing cancer care. For instance, in June 2023, a team of researchers from Hiromitsu Haba at the RIKEN Nishina Center for Accelerator-Based Science (RNC) and RIKEN Cluster for Pioneering Research (CPR) in Japan developed a new technique that offers less harmful and more precise alternatives to currently available treatments. As clinical trials progress for the technique, it is expected to attract more investments and propel advancements in breast cancer treatment, allowing the country to offer innovative oncology solutions to its patient population.
Targeted Therapies Hold Major Market Share
The segment's dominance can be attributed to the higher efficacy and safety of targeted therapies and their ability to address specific genetic mutations in cancer cells. The rapid advancements in companion diagnostics and the adoption of precision medicine are further enabling physicians to match targeted therapies to the unique genetic profiles of the patients, improving their effectiveness. Additionally, a wide number of targeted therapies are also receiving approval in Japan. For instance, in March 2024, AstraZeneca plc received approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Truqap (capivasertib) plus Faslodex (fulvestrant) for breast cancer. The company received approval for the recurrent or unresectable AKT serine/threonine kinase 1 or phosphatase, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, and tensin homolog-altered hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The drug combination is intended for adult patients who have progressed following endocrine therapy. The approval is based on the data collected from the double-blind, randomized, global CAPItello-291 Phase III clinical trial.
Impact of the U.S. Tariff on Japan Breast Cancer Treatment Market
- The tariffs are expected to bolster the costs for advanced equipment such as biopsy devices and mammography machines, potentially affecting the accessibility and affordability of early breast cancer detection technologies.
- Various healthcare institutions may face budget issues and financial strain, limiting their ability to acquire new equipment and therapeutic solutions, thus impacting the quality of care provided to the patient population.
- Meanwhile, the tariffs are expected to encourage domestic manufacturers to focus on product innovation and production, reducing their reliance on imports and mitigating the adverse effects associated with the evolution of trade policies.
Key Players Landscape and Outlook
The key players of the market are focusing on investing in product innovations and launching new drugs in the country. For instance, in December 2024, Daiichi Sankyo Company, Limited received approval from Japan's MHLW for its trophoblast cell surface antigen 2 (Trop2)-directed antibody-drug conjugate (ADC) for treating adults with hormone receptor (HR)-positive, HER2-negative recurrent or unresectable breast cancer after prior chemotherapy. This approval expands the therapeutic solutions available for advanced stages of breast cancer and is encouraging a wider adoption of ADCs. Such launches are providing improved efficacy and safety as compared to conventional treatment solutions, positively influencing the market's expansion.
1. Project Scope and Definitions
2. Research Methodology
3. Impact of the U.S. Tariff on Japan Breast Cancer Treatment Market
4. Executive Summary
5. Japan Breast Cancer Treatment Market Outlook, FY2019-FY2033F
5.1. Market Size Analysis & Forecast
5.1.1. By Value
5.2. Market Share Analysis & Forecast
5.2.1. By Type
5.2.1.1. Ductal Carcinoma In Situ (DCIS)
5.2.1.2. Invasive Ductal Carcinoma (IDC)
5.2.1.3. Lobular Carcinoma In Situ (LCIS)
5.2.1.4. Invasive Lobular Cancer (ILC)
5.2.1.5. Triple Negative Breast Cancer
5.2.1.6. Inflammatory Breast Cancer (IBC)
5.2.1.7. Metastatic Breast Cancer
5.2.1.8. Breast Cancer During Pregnancy
5.2.1.9. Other Types
5.2.2. By Treatment Type
5.2.2.1. Surgery
5.2.2.2. Radiation Therapy
5.2.2.3. Chemotherapy
5.2.2.4. Hormonal Therapy
5.2.2.4.1. Selective Estrogen Receptor Modulators
5.2.2.4.2. Aromatase Inhibitors
5.2.2.4.3. Estrogen Receptor Downregulators
5.2.2.5. Targeted Therapy
5.2.2.5.1. Abemaciclib
5.2.2.5.2. Adotrastuzumab Emtansine
5.2.2.5.3. Everolimus
5.2.2.5.4. Trastuzumab
5.2.2.5.5. Ribociclib
5.2.2.5.6. Palbocicib
5.2.2.5.7. Pertuzumab
5.2.2.5.8. Olaparib
5.2.2.5.9. Others
5.2.2.6. Immunotherapy
5.2.2.7. Others
5.2.3. By End-user
5.2.3.1. Cancer Research Institutes
5.2.3.2. Hospitals
5.2.3.3. Ambulatory Surgical Centers
5.2.3.4. Others
5.2.4. By Region
5.2.4.1. North [Hokkaido and Tohoku]
5.2.4.2. Central [Kanto and Chubu]
5.2.4.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
5.3. Market Map Analysis, FY2025
5.3.1. By Type
5.3.2. By Treatment Type
5.3.3. By End-user
5.3.4. By Region
6. Demand Supply Analysis
7. Value Chain Analysis
8. Porter's Five Forces Analysis
9. PESTLE Analysis
10. Pricing Analysis
11. Market Dynamics
11.1. Market Drivers
11.2. Market Challenges
12. Market Trends and Developments
13. Regulatory Framework and Innovation
13.1. Regulatory Approvals
13.2. Clinical Trials
14. Patent Landscape
15. Case Studies
16. Competitive Landscape
16.1. Competition Matrix of Top 5 Market Leaders
16.2. SWOT Analysis for Top 5 Players
16.3. Key Players Landscape for Top 10 Market Players
16.3.1. Novartis Pharma K.K.
16.3.1.1. Company Details
16.3.1.2. Key Management Personnel
16.3.1.3. Products and Services
16.3.1.4. Financials (As Reported)
16.3.1.5. Key Market Focus and Geographical Presence
16.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
16.3.2. Pfizer Japan Inc.
16.3.3. Eisai Co., Ltd.
16.3.4. Merck & Co., Inc.
16.3.5. Kyowa Kirin Co., Ltd.
16.3.6. Eli Lilly Japan K.K.
16.3.7. Bristol-Myers Squibb K.K.
16.3.8. AstraZeneca plc
16.3.9. Sanofi K.K.
16.3.10. Daiichi Sankyo Company, Limited
*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.
17. Strategic Recommendations
18. About Us and Disclaimer
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security